Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats

J Neurotrauma. 2001 Apr;18(4):369-76. doi: 10.1089/089771501750170912.

Abstract

The nuclear enzyme poly(ADP-ribose) polymerase (PARP), which has been shown to be activated following experimental traumatic brain injury (TBI), binds to DNA strand breaks and utilizes nicotinamide adenine dinucleotide (NAD) as a substrate. Since consumption of NAD may be deleterious to recovery in the setting of CNS injury, we examined the effect of a potent PARP inhibitor, GPI 6150, on histological outcome following TBI in the rat. Rats (n = 16) were anesthetized, received a preinjury dose of GPI 6150 (30 min; 15 mg/kg, i.p.), subjected to lateral fluid percussion (FP) brain injury of moderate severity (2.5-2.8 atm), and then received a second dose 3 h postinjury (15 mg/kg, i.p.). Lesion area was examined using Nissl staining, while DNA fragmentation and apoptosis-associated cell death was assessed with terminal deoxynucleotidyl-transferase-mediated biotin-dUTP nick end labeling (TUNEL) with stringent morphological evaluation. Twenty-four hours after brain injury, a significant cortical lesion and number of TUNEL-positive/nonapoptotic cells and TUNEL-positive/apoptotic cells in the injured cortex of vehicle-treated animals were observed as compared to uninjured rats. The size of the trauma-induced lesion area was significantly attenuated in the GPI 6150-treated animals versus vehicle-treated animals (p < 0.05). Treatment of GPI 6150 did not significantly affect the number of TUNEL-positive apoptotic cells in the injured cortex. The observed neuroprotective effects on lesion size, however, offer a promising option for further evaluation of PARP inhibition as a means to reduce cellular damage associated with TBI.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Benzopyrans / pharmacology*
  • Brain Injuries / enzymology*
  • Brain Injuries / genetics
  • Brain Injuries / pathology*
  • DNA Fragmentation / drug effects
  • Enzyme Inhibitors / pharmacology*
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Isoquinolines / pharmacology*
  • Male
  • Neuroprotective Agents / pharmacology*
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Benzopyrans
  • Enzyme Inhibitors
  • GPI 6150
  • Isoquinolines
  • Neuroprotective Agents
  • Poly(ADP-ribose) Polymerase Inhibitors